ImmunoChem Therapeutics, LLC

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
ImmunoChem Therapeutics, a Phase 2 clinical stage Northwestern University spin-out, is developing two clinical assets targeting abnormal brain inflammation, a major contributor to cognitive decline in Alzheimer’s disease, other dementias, brain injury, and stroke. The development of this novel class of drugs targeting neuroinflammation has been supported by non-dilutive, peer-reviewed Fast Track SBIR and STTR grants from NIH, and by Alzheimer’s Association and Alzheimer's Drug Discovery Foundation.
ImmunoChem is raising private funds to complete Phase 2a clinical trial in an orphan indication, and is also seeking potential partners. Because our drug development platform targets neuroinflammation and disease progression pathways common across several diseases, later clinical development can be staged for additional major or neglected CNS indications.
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
MW189
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
ImmunoChem Therapeutics, LLC